This week, we explore the world of investigational medicines that have the potential to revolutionize the landscape of hearing healthcare, from restoration to treatment and prevention. Our guest for this insightful discussion is Nawal Ouzren, the CEO of the French biotech firm, Sensorion. With a distinguished career that includes significant roles at Shire and Baxter, Ouzren sheds light on Sensorion's mission, centered around three fundamental pillars: addressing hearing loss post-onset, proactive strategies for hearing loss prevention, and developing groundbreaking gene therapies to combat congenital deafness.